Clenbuterol (Beta-2 Adrenergic Agonist with Anabolic Misuse Liability)
Clenbuterol (Beta-2 Adrenergic Agonist with Anabolic Misuse Liability) is classified under Group B (Pharmacological & Prohibited Performance-Enhancing Substances). It is NOT recommended as an athletic performance aid. This monograph provides objective clinical pharmacology, toxicology, Indian statutory regulation, and WADA anti-doping education only—it never provides doping cycles, stacking regimens, or testing-evasion instructions. Any legitimate therapeutic use requires specialist medical diagnosis and supervision.
1. Generic or Accepted Substance Name & Classifications
Accepted Name: Clenbuterol (Beta-2 Adrenergic Agonist with Anabolic Misuse Liability)
Common Names, Synonyms & Classifications: Clenbuterol Hydrochloride; 4-Amino-alpha-[(tert-butylamino)methyl]-3,5-dichlorobenzyl alcohol
Section Classification: Group B — Pharmacological & Prohibited Performance-Enhancing Substances (PERF-B15)
2. Pharmacological Class
Long-Acting Sympathomimetic Beta-2 Adrenergic Receptor Agonist (Classified under WADA S1.2 Other Anabolic Agents)
3. Mechanism of Action
Potently stimulates Beta-2 (and partially Beta-1/Beta-3) adrenergic receptors, activating adenylyl cyclase to increase intracellular cAMP and Protein Kinase A (PKA). In bronchial smooth muscle this causes bronchodilation; in adipocytes and skeletal muscle at high supratherapeutic doses in animal models it stimulates hormone-sensitive lipase (lipolysis) and transient Beta-2-mediated protein accretion—accompanied in humans by severe sympathetic cardiac and metabolic toxicity.
4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)
Pharmacological Effect: Long-acting adrenergic stimulation (terminal half-life ~25–39 hours) and lipolysis. Anti-Doping & Clinical Reality: Strictly prohibited at all times. Unlike inhaled short/long-acting beta-2 agonists used clinically for asthma (Salbutamol, Formoterol, Salmeterol, Vilanterol—which have therapeutic inhaled WADA thresholds), Clenbuterol is classified under WADA S1.2 (Other Anabolic Agents) and is completely prohibited at all times due to high risks of myocardial necrosis, ventricular arrhythmias, and severe hypokalaemia.
5. Quality of Scientific Evidence
Evidence Assessment: PROHIBITED DOPING AGENT (WADA S1.2) — Severe Cardiotoxic and Arrhythmogenic Hazard in Humans
6. Approved Medical Uses (Where Applicable)
Not approved by the US FDA for human use; in most jurisdictions (and veterinary practice) restricted to equine bronchodilation or tightly restricted respiratory indications where safer selective inhaled beta-2 agonists (Salbutamol IP, Levosalbutamol IP, Formoterol IP) have superseded it.
7. Sports-Related Uses, Misuse Patterns & Contamination Risks
Illicitly abused in bodybuilding and weight-category sports as a 'fat burner' or cutting agent, or encountered as an undeclared contaminant in illicit weight-loss powders (and historically in livestock meat in regions where illegal veterinary growth promotion occurred).
8. Adverse Effects & Serious Safety Risks
Severe sinus tachycardia, supraventricular and ventricular arrhythmias, myocardial ischaemia and focal myocardial necrosis, acute intracellular potassium shift causing severe hypokalaemia (precipitating QTc prolongation and Torsades de Pointes), hyperglycaemia, lactic acidosis, coarse skeletal muscle tremor, severe agitation/insomnia, and thyrotoxicosis-like hyperthermia.
9. Contraindications & Precautions
ABSOLUTELY CONTRAINDICATED for weight loss, athletic enhancement, ischaemic heart disease, tachyarrhythmias, hypertrophic obstructive cardiomyopathy, hyperthyroidism, and pregnancy.
10. Drug Interactions
Severe hypokalaemia and arrhythmia potentiation when combined with loop/thiazide diuretics, theophylline, or corticosteroids; hypertensive crisis and fatal arrhythmias with MAO inhibitors, tricyclic antidepressants, or other sympathomimetics/caffeine.
11. Clinical & Laboratory Monitoring Considerations
Patients presenting with Clenbuterol toxicity require continuous 12-lead ECG monitoring, urgent serum potassium, magnesium, glucose, lactate, and cardiac troponin assays (managed clinically with intravenous potassium repletion and cautious beta-blockade).
12. Dependence, Misuse or Withdrawal Concerns
Rapid beta-2 receptor downregulation/desensitisation (tachyphylaxis) leads illicit users to escalate doses into cardiotoxic ranges.
13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)
Not included in NLEM 2022; unapproved for weight loss or bodybuilding in India under CDSCO regulations. Safer compendial inhaled bronchodilators (Salbutamol IP, Levosalbutamol IP, Formoterol IP, Salmeterol IP) are the standard of care for asthma/COPD.
14. Official WADA Prohibited-List Status
PROHIBITED AT ALL TIMES (In-Competition and Out-of-Competition) under WADA Prohibited List Category S1.2 (Other Anabolic Agents — Non-Specified Substance).
15. Authoritative Source References & Date of Last Verification
Date of Last Verification: 11 November 2026